Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.

Cases and Conversations: Clinical Considerations for the Use of DOAC Reversal Agents.

Release Date: October 20, 2020
Expiration Date: October 20, 2021

Activity Overview

This online, on-demand virtual symposium brings together a renowned group of experts in the management of anticoagulation therapies. The most challenging adverse event of direct oral anticoagulants (DOACs), is the increased risk of bleeding. It is vital for clinicians to identify patients with or at risk for severe or uncontrollable hemorrhage and assess whether to administer a DOAC reversal agent. This activity discusses the clinical indications for DOAC reversal agents, current guidelines for reversal therapies, the roles of clinicians across the different disciplines, and the clinical implications within each therapeutic area. Experts discuss a range of patient cases that bring together the elements of clinical decision making on when to administer DOAC reversal therapy in clinical practice.

This educational activity is an archive of the live virtual symposium held on October 5, 2020.


Acknowledgement of Support

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward physicians who treat patients with, or at high risk of, severe bleeding on anticoagulant therapy. Cardiologists, emergency physicians, and other health care professionals interested in the management of acute hemorrhage are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Identify factors associated with high risk of severe bleeding in patients using DOAC therapy
  • Evaluate the efficacy and safety of reversal agents for DOAC therapy
  • Discuss the application of institutional best practices for reversal of DOAC therapy in patients with, or at high risk of, severe bleeding

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Geoffrey D. Barnes, MD, MSc, FACC
Geoffrey D. Barnes, MD, MSc, FACC
Assistant Professor of Cardiovascular Medicine and Vascular Medicine
Department of Internal Medicine
Division of Cardiovascular Medicine
University of Michigan Medical School
Ann Arbor, MI

Disclosures: Grant Research Support: Pfizer/Bristol Myers Squib; Consultant: AMAG Pharmaceuticals, Janssen, Pfizer/Bristol Myers Squib, Portola Pharmaceuticals, Inc.

Lana Castellucci, MD, FRCPC, MSc
Lana Castellucci, MD, FRCPC, MSc
Scientist, Clinical Epidemiology Program
Ottawa Hospital Research Institute
Assistant Professor, Faculty of Medicine
University of Ottawa
Ottawa, Canada

Disclosures: Grant Research Support: Bayer, Bristol Myers Squib, Boehringer lngelheim, Leo Pharma, Pfizer, Sanofi; Other: Honoraria from Academy for Continued Advancement in Education

Rachel Rosovsky, MD, MPH
Rachel Rosovsky, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Department of Hematology and Oncology
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: Institutional research grant support: Bristol Myers Squib; Consultant: Bristol Myers Squib, Dova, Janssen

Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Professor, Institute of Health Innovations & Outcomes Research
Feinstein Institutes for Medical Research
Director, Anticoagulation and Clinical Thrombosis Services
Northwell Health at Lenox Hill Hospital
New York, NY

Disclosures: Grant Research Support: Janssen, Boehringer Ingelheim; Consultant: Atlas Group, Bayer, Dova, Janssen, Boehringer Ingelheim, Portola Pharmaceuticals, Inc.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By